/ EN
2025-12-08 00:00 United States Policy & Regulation Regulatory Approval Translated from EN

FDA Clears Ceribell Delirium Monitor System

Summary The FDA cleared the Ceribell Delirium Monitor System on December 8, 2025, finding it substantially equivalent under submission number K251936 through the traditional 510(k) pathway. The agency classifies it as a Neuropsychiatric Interpretative Electroencephalograph Assessment Aid, a Class II device under regulation 882.1440, with neurology as the assigned review panel. The category covers devices that derive neuropsychiatric assessments from EEG signals; Ceribell's earlier products in this line target seizure monitoring in emergency and intensive care settings.
Why it matters Moving from seizure detection to a delirium assessment aid takes Ceribell from flagging an electrical event to scoring a mental state, a materially broader claim and the reason the neuropsychiatric assessment-aid category is worth watching.

BCIwiki (bciwiki.com) — Ceribell, Inc. received an FDA 510(k) decision of Substantially Equivalent for Ceribell Delirium Monitor System on December 8, 2025, under submission number K251936. The submission followed the Traditional 510(k) clearance pathway.

FDA lists the product under the device classification name Neuropsychiatric Interpretative Electroencephalograph Assessment Aid. It is a Class 2 device under regulation number 882.1440, assigned to the Neurology advisory committee. The classification covers devices that derive neuropsychiatric assessments from EEG signals; Ceribell's earlier products in this line target seizure monitoring in emergency and intensive care settings.

Compiled by BCIwiki from public sources

Sources · 1

Ceribell timeline

2026-06 FDA Clears Ceribell Monitor for Bedside EEG Recording 2026-06 FDA Clears Ceribell Neurology Review Software 2025-11 FDA Clears Ceribell Infant Seizure Software All entries →
Read original ↗
Suggest a correction Revisions · none / EN
© 2026 BCIwiki.com Digest Topics Tips Subscribe Revisions About